145 related articles for article (PubMed ID: 11283143)
1. Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy.
Sigsgaard T; Herrstedt J; Handberg J; Kjaer M; Dombernowsky P
J Clin Oncol; 2001 Apr; 19(7):2091-7. PubMed ID: 11283143
[TBL] [Abstract][Full Text] [Related]
2. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
Sigsgaard T; Herrstedt J; Andersen LJ; Havsteen H; Langer SW; Kjaerbøl AG; Lund H; Kjaer M; Dombernowsky P
Br J Cancer; 1999 May; 80(3-4):412-8. PubMed ID: 10408847
[TBL] [Abstract][Full Text] [Related]
3. Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy.
Sigsgaard T; Herrstedt J; Christensen P; Andersen O; Dombernowsky P
Support Care Cancer; 2000 May; 8(3):233-7. PubMed ID: 10789966
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy.
Herrstedt J; Sigsgaard TC; Nielsen HA; Handberg J; Langer SW; Ottesen S; Dombernowsky P
Support Care Cancer; 2007 Apr; 15(4):417-26. PubMed ID: 17093916
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer.
Herrstedt J; Sigsgaard T; Handberg J; Schousboe BM; Hansen M; Dombernowsky P
J Clin Oncol; 1997 Apr; 15(4):1690-6. PubMed ID: 9193370
[TBL] [Abstract][Full Text] [Related]
6. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.
Herrstedt J; Sigsgaard T; Boesgaard M; Jensen TP; Dombernowsky P
N Engl J Med; 1993 Apr; 328(15):1076-80. PubMed ID: 8455664
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design.
Nathan PC; Tomlinson G; Dupuis LL; Greenberg ML; Ota S; Bartels U; Feldman BM
Support Care Cancer; 2006 Mar; 14(3):268-76. PubMed ID: 16052316
[TBL] [Abstract][Full Text] [Related]
8. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group.
Lebeau B; Depierre A; Giovannini M; Rivière A; Kaluzinski L; Votan B; Hédouin M; d'Allens H
Ann Oncol; 1997 Sep; 8(9):887-92. PubMed ID: 9358940
[TBL] [Abstract][Full Text] [Related]
10. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis.
Khamales S; Bethune-Volters A; Chidiac J; Bensaoula O; Delgado A; Di Palma M
Anticancer Drugs; 2006 Feb; 17(2):217-24. PubMed ID: 16428941
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
Bloch J; Rixe O; Meric JB; Delgado A; Khayat D
Curr Med Res Opin; 2005 Nov; 21(11):1763-71. PubMed ID: 16307696
[TBL] [Abstract][Full Text] [Related]
14. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
16. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
17. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.
Kaizer L; Warr D; Hoskins P; Latreille J; Lofters W; Yau J; Palmer M; Zee B; Levy M; Pater J
J Clin Oncol; 1994 May; 12(5):1050-7. PubMed ID: 8164029
[TBL] [Abstract][Full Text] [Related]
18. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
19. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
Lofters WS; Pater JL; Zee B; Dempsey E; Walde D; Moquin JP; Wilson K; Hoskins P; Guevin RM; Verma S; Navari R; Krook JE; Hainsworth J; Palmer M; Chin C
J Clin Oncol; 1997 Aug; 15(8):2966-73. PubMed ID: 9256141
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
